Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Aligos Therapeutics Inc (NQ: ALGS ) 0.5251 +0.0450 (+9.37%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 508,904 Open 0.4821 Bid (Size) 0.5010 (9) Ask (Size) 0.5250 (1) Prev. Close 0.4801 Today's Range 0.4701 - 0.5500 52wk Range 0.3482 - 1.200 Shares Outstanding 42,940,089 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Aligos Therapeutics Announces Reverse Stock Split August 15, 2024 From Aligos Therapeutics Via GlobeNewswire Aligos Therapeutics Strengthens Board with Two New Independent Directors August 08, 2024 From Aligos Therapeutics Via GlobeNewswire Performance YTD -25.98% -25.98% 1 Month +6.51% +6.51% 3 Month -21.76% -21.76% 6 Month -17.93% -17.93% 1 Year -38.94% -38.94% More News Read More Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results August 06, 2024 From Aligos Therapeutics Via GlobeNewswire Recap: Aligos Therapeutics Q4 Earnings March 12, 2024 Via Benzinga Aligos Therapeutics Earnings Preview March 11, 2024 Via Benzinga Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024 July 30, 2024 From Aligos Therapeutics Via GlobeNewswire Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal July 27, 2024 Via Talk Markets Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd. July 22, 2024 From Aligos Therapeutics Via GlobeNewswire Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB July 10, 2024 From Aligos Therapeutics Via GlobeNewswire Aligos Therapeutics Presents Positive Data at the EASL Congress 2024 June 05, 2024 From Aligos Therapeutics Via GlobeNewswire Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024 May 22, 2024 From Aligos Therapeutics Via GlobeNewswire Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH May 21, 2024 From Aligos Therapeutics Via GlobeNewswire ALGS Stock Earnings: Aligos Therapeutics Misses EPS for Q1 2024 May 07, 2024 Via InvestorPlace Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results May 07, 2024 From Aligos Therapeutics Via GlobeNewswire Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024 April 30, 2024 From Aligos Therapeutics Via GlobeNewswire Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study April 25, 2024 From Aligos Therapeutics Via GlobeNewswire Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD April 25, 2024 From Aligos Therapeutics Via GlobeNewswire Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024 April 09, 2024 From Aligos Therapeutics Via GlobeNewswire Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects April 03, 2024 From Aligos Therapeutics Via GlobeNewswire Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies March 27, 2024 From Aligos Therapeutics Via GlobeNewswire Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects March 18, 2024 From Aligos Therapeutics Via GlobeNewswire 12 Health Care Stocks Moving In Friday's After-Market Session March 15, 2024 Via Benzinga Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results March 12, 2024 From Aligos Therapeutics Via GlobeNewswire Earnings Scheduled For March 12, 2024 March 12, 2024 Via Benzinga Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024 March 05, 2024 From Aligos Therapeutics Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.